Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer
Standard
Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer : New Treatments and Implementation of Therapies with Companion Diagnostics. / Lüftner, Diana; Schneeweiss, Andreas; Hartkopf, Andreas D; Müller, Volkmar; Wöckel, Achim; Janni, Wolfgang; Ettl, Johannes; Belleville, Erik; Schütz, Florian; Thill, Marc; Huober, Jens; Fasching, Peter A; Kolberg, Hans-Christian; Pöschke, Patrik; Welslau, Manfred; Overkamp, Friedrich; Tesch, Hans; Fehm, Tanja N; Lux, Michael P.
in: GEBURTSH FRAUENHEILK, Jahrgang 80, Nr. 4, 04.2020, S. 391-398.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer
T2 - New Treatments and Implementation of Therapies with Companion Diagnostics
AU - Lüftner, Diana
AU - Schneeweiss, Andreas
AU - Hartkopf, Andreas D
AU - Müller, Volkmar
AU - Wöckel, Achim
AU - Janni, Wolfgang
AU - Ettl, Johannes
AU - Belleville, Erik
AU - Schütz, Florian
AU - Thill, Marc
AU - Huober, Jens
AU - Fasching, Peter A
AU - Kolberg, Hans-Christian
AU - Pöschke, Patrik
AU - Welslau, Manfred
AU - Overkamp, Friedrich
AU - Tesch, Hans
AU - Fehm, Tanja N
AU - Lux, Michael P
PY - 2020/4
Y1 - 2020/4
N2 - For patients with locally advanced or metastatic breast cancer, new and effective therapies such as CDK4/6 inhibitors, PARP inhibitors and a PD-L1 inhibitor have been introduced in recent years. This review presents an update on the available studies with their data. In addition, two innovative anti-HER2 therapies are presented (trastuzumab-deruxtecan and tucatinib) for which the results from new studies have been reported. Molecular tests offer the possibility of defining patient populations or also monitoring courses of therapy. This can help identify patients with specific characteristics in order to provide them with individually targeted therapy within the framework of studies. In a large study, the benefit of such a biomarker study was able to be described for the first time.
AB - For patients with locally advanced or metastatic breast cancer, new and effective therapies such as CDK4/6 inhibitors, PARP inhibitors and a PD-L1 inhibitor have been introduced in recent years. This review presents an update on the available studies with their data. In addition, two innovative anti-HER2 therapies are presented (trastuzumab-deruxtecan and tucatinib) for which the results from new studies have been reported. Molecular tests offer the possibility of defining patient populations or also monitoring courses of therapy. This can help identify patients with specific characteristics in order to provide them with individually targeted therapy within the framework of studies. In a large study, the benefit of such a biomarker study was able to be described for the first time.
U2 - 10.1055/a-1111-8775
DO - 10.1055/a-1111-8775
M3 - SCORING: Journal article
C2 - 32322108
VL - 80
SP - 391
EP - 398
JO - GEBURTSH FRAUENHEILK
JF - GEBURTSH FRAUENHEILK
SN - 0016-5751
IS - 4
ER -